“A conspicuous knowledge gap now exists about” the safety of gadolinium-based contrast agents—Dr. Stephen Brown, Harvard Medical School, in
The Need for National Guidance Around Informed Consent About GBCA Safety
tandfonline.com/doi/abs/10.108…
#gadolinium #radiology #patientsafety

“The research protocol under discussion highlights where the [National Institutes of Health] Roadmap around [gadolinium-based contrast agents] falls short,” because informed consent about gadolinium deposition could be left out—Dr. Stephen Brown
tandfonline.com/doi/abs/10.108…

“The [Institutional Review Board] should first clarify that gadolinium deposition is NOT INCIDENTAL in this study,” [emphasis added]—Dr. Stephen Brown, Harvard Medical School, in
The Need for National Guidance Around Informed Consent About GBCA Safety
tandfonline.com/doi/abs/10.108…

“The deposition [of #gadolinium ☠️] and its consequences are the primary investigative targets; THE PARTICIPANTS ARE SPECIFICALLY AT RISK,” [emphasis added]—Dr. Stephen Brown, Harvard Medical School
tandfonline.com/doi/abs/10.108…
#radiology #patientsafety #neurology #nephrology

“It is empirically groundless to establish that [Institutional Review Boards] or individual investigators should retain decisional discretion over the balance of harms and benefits for individual patients” exposed to gadolinium-based contrast agents.
tandfonline.com/doi/abs/10.108…

“Discretion should be left to individual participants following informed consent” about gadolinium retention due to gadolinium-based contrast agent exposure. Dr. Stephen Brown, Harvard Medical School
tandfonline.com/doi/abs/10.108…
#gadolinium #radiology #patientsafety #ethics

Gadolinium-based contrast agents lead to the retention of gadolinium—a heavy rare earth metal—in every organ, including the brain.

Should patients be informed of long term gadolinium retention before they are exposed to gadolinium-based contrast agents?